• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
3-Bromo-4-fluorobenzaldehyde
5-Methyl-1,3,4-oxadiazol2(3H)-one
4-Amino-6-methyl-3 oxo2,3, 4,5-tetrahydro 1.2.4-triazine hydrochloride
4-Acetylamino-6-methyl -3-oxo-2,3,4,5-tetrahydro-1,2,4-triazine
3-Pyridinecarboxaldehyde
Ethyl 3 Fluorobenzoate

EU drug regulator records 415 cases of possible rare blood clotting

firstwordpharmaJune 18, 2021

Tag: AstraZeneca , Johnson & Johnson , COVID-19 , Vaccine

The EU drug regulator said on Thursday it has received reports of 415 possible cases of thrombosis with thrombocytopenia syndrome in the European Economic Area (EEA), out of over 50 million people who have gotten AstraZeneca and Johnson & Johnson's COVID-19 vaccines, as reported in Fidelity.

EU drug regulator records 415 cases of possible rare blood clotting

Specifically, there have been 10 possible cases among just under 6 million people who received Johnson & Johnson's shot in the EEA, and 405 cases among 45 million who received AstraZeneca's shot, stated Georgy Genov, head of pharmacovigilance at the European Medicines Agency.


Previous:Alzamend Neuro Announces Closing of Initial Public Offering and Full Exercise of Underwriter’s Over-allotment Option for Gross Proceeds of $14.4 Million

Next:U.S. Buys 200 Million Extra Moderna Vaccine Doses, as Possible Booster Shots

Related News

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

BioPharmaSpec, the leading global Contract Research Organization (CRO) for Discovery and Preclinical Characterization of Biopharmaceuticals, has officially announced three new European facilities.

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

EU drug regulator records 415 cases of possible rare blood clotting | Pharmasources.com

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

PharmaSourcesNovember 15, 2024

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

You may like
More>>

Meningococcal Polysaccharide Vaccine Group ACYW135

Meningococcal Polysaccharide Vaccine Group ACYW135
Quadrivalent Influenza Vaccine in 2022

Quadrivalent Influenza Vaccine in 2022
Hualan Group ACYW135 Meningococcal Polysaccharide Vaccine with lower side effect and high quality

Hualan Group ACYW135 Meningococcal Polysaccharide Vaccine with lower side effect and high quality
trivalent flu vaccine

trivalent flu vaccine
Influenza Vaccine(Split Virion),Inactivated

Influenza Vaccine(Split Virion),Inactivated
Poultry Vaccine Series 2

Poultry Vaccine Series 2
Hualan's Trivalent Flu Vaccine

Hualan's Trivalent Flu Vaccine
2024-2025 quadrivalent/trivalent flu vaccine

2024-2025 quadrivalent/trivalent flu vaccine
Hualan Biological H7N9 Inactivated Influenza Vaccine

Hualan Biological H7N9 Inactivated Influenza Vaccine
B28 pp 100ml autoclaved vaccine bottle

B28 pp 100ml autoclaved vaccine bottle

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service